Wednesday, June 16, 2004

Welcome and Opening Remarks
Adel Mahmoud, M.D., Ph.D. 
Chair, Forum on Microbial Threats
President, Merck Vaccines

Keynote Address:  John M. Barry, Distinguished Visiting Scholar, The Center for Bioenvironmental Research at Tulane and Xavier Universities, and Author of The Great Influenza: The Epic Story of the Deadliest Plague in History

  PLANNING AND PREPAREDNESS FOR PANDEMIC INFLUENZA

Session I: Global and National Preparedness Strategies
Moderator: Adel Mahmoud, M.D., Ph.D., Chair, Forum on Microbial Threats/President, Merck Vaccines

WHO: Priority Public Health Interventions Before and During an Influenza Pandemic    
Klaus Stohr, D.V.M., Project Leader, Global Influenza Programme, Department of Communicable Disease Surveillance and Response, The World Health Organization, Geneva
View Slides

U.S. Government Preparedness Plan
Bruce Gellin, M.D., Director, National Vaccine Program Office, U.S. Department of Health and Human Services
View Slides

Q&A

Session II: Response and Discussion of Preparedness Planning
Moderator:  Stanley Lemon, M.D., Vice Chair, Forum on Microbial Threats/ Dean of Medicine, The University of Texas Branch at Galveston

Response to Session I Presentations: Open Discussion

Panel Discussants:
David Fedson, M.D., Sergy Haut, France               
Nancy Cox, Ph.D., Chief, Influenza Branch, CDC and Director, WHO Collaborating Centre for Surveillance, Epidemiology, and Control of Influenza
Dennis Perrotta, Ph.D., State Epidemiologist, Texas
Peter Shult, Ph.D., Director, Communicable Disease Division and Emergency Laboratory Response, Wisconsin State Laboratory of Hygiene

Session III: Obstacles and Opportunities for Optimal Preparednessess
Moderator: Gary Roselle, M.D., Program Director for Infectious Diseases, Department of Veterans Affairs Central Office

Partnering with the Private Medical System
Gordon Grundy, M.D., Regional Medical Director, Aetna, Inc.

Discussion

Vaccine Development and Production Issues
Philip Hosbach, Vice President of New Products and Immunization Policy, Aventis Pasteur SA
View Slides

Discussion

Ensuring an Adequate Stockpile of Antivirals
Paul Brown, Ph.D., Global Task Force Leader for Tamiflu Pandemic Planning, F. Hoffman La-Roche Pharmaceuticals, Switzerland
View Slides

Discussion        

Chasing the Elusive Virus: Understanding the Challenges of Future by Examining the Past
Jeffrey Taubenberger, M.D., Chair, Department of Molecular Pathology, Armed Forces Institute of Pathology, U.S. Department of Defense
View Slides

Discussion

Session IV: Panel Discussion—Innovating Past Barriers
Moderator: Joshua Lederberg, Ph.D., Nobel Laureate, Sackler Foundation Scholar, Rockefeller University    

Strategies for control of influenza by targeting braodly conserved viral features:
Suzanne Epstein, Ph.D., Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
View Slides

Mathematical Modeling: Containing pandemic influenza with vaccines and antivirals:
Ira Longini, M.D., Rollins School of Public Health, Emory University, Atlanta, GA
View Slides
Marc Lipsitch, Ph.D., Harvard School of Public Health, Boston, MA
View Slides

"Insuring" for a Better Response:
Martin Meltzer, Ph.D., National Center for Infectious Diseases, U.S. Centers for Disease Control and Prevention
View Slides

Coordination between the Public and Private Sectors:
Jonathan B. Perlin, M.D., Ph.D., MSHA, FACP, Acting Under Secretary for Health, Department of Veterans Affairs
View Slides